Dr. Najeebah Abdullah Bade, MD

Dr. Bade practices at Presbyterian Hospital in Albuquerque, New Mexico, part of Presbyterian Healthcare Services.

Dr. Bade's NPI, 1043500150, was assigned on April 10, 2011. Dr. Bade graduated from Georgetown University School Of Medicine in 2011. Dr. Bade holds Virginia license 0101256484.

Dr. Bade's primary practice is Presbyterian Hospital, at 1100 Central Avenue SE, Albuquerque, NM 87106 in Bernalillo County. The practice phone is (505) 724-8386.

Dr. Bade's primary practice is Presbyterian Hospital in Albuquerque, New Mexico, part of Presbyterian Healthcare Services. Dr. Bade is also affiliated with Inova Fairfax Hospital. The medical group on file is Presbyterian Medical Group. Dmand AI also links Dr. Bade to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bade practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Bade's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Bade is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Bade's licenses on file in 3 states: Virginia, California and District of Columbia.

Dmand AI lists chronic anemia, chronic embolism thrombosis, deep vein thrombosis (DVT), prostate cancer and purpura and thrombocytopenia among the conditions Dr. Bade treats.

CMS data shows 320 Medicare services from Dr. Bade across 6 procedure codes in 2024, for 236 Medicare patients. Medicare paid $25,890 for them.

CMS counts 236 Medicare patients who saw Dr. Bade in 2024. The largest group is 75 to 84, with 100 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.40, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bade's median patient age at 53, with 63% women.

In 2024, Dr. Bade wrote 310 Medicare Part D claims for 72 patients. 36% of them were for generic drugs. CMS names the drug for 254 of them, across 7 drugs with 11 or more claims each, at $392,493 in total drug cost. In 2023, CMS named 158 claims across 6 drugs.

Dr. Bade accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bade as offering telehealth.

Dmand AI links 11 papers to Dr. Bade, published from 2016 to 2024. 2017 was the busiest year, with 2. The most frequent topics are Antineoplastic Agents. Dr. Bade's most frequent co-authors are Maria R. Baer, MD, Ashkan Emadi, MD, PhD and Jennie Y. Law, MD.

CMS Open Payments shows 5 general payments to Dr. Bade from 5 drug and device companies from 2017 to 2024. Food and beverage make up the largest share, 63% of the total. Genentech, Inc. paid the most, $105.

Dr. Bade graduated from Georgetown University School Of Medicine in 2011. Dr. Bade is a member of ASH, Foundation for Women and Girls with Blood Disorders, HTRS and International Society for Thrombosis and Haemostasis.

Dr. Bade is in network with 17 carriers, including Elevance, United Healthcare and Cigna. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.